Month: May 2020

CAMBRIDGE, Mass., May 11, 2020 (GLOBE NEWSWIRE) — Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that management will participate in a fireside chat at the virtual BofA Securities 2020 Health Care Conference on May 14, 2020 at 1:40 p.m. ET.A live audio webcast will be available through the Investor Relations section of the Fulcrum website at https://ir.fulcrumtx.com/events-and-presentations. An archived replay will be available on the Company’s website for 90 days.About Fulcrum Therapeutics Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases in areas of high unmet medical need. Fulcrum’s proprietary...

Worldwide Ocaliva net sales of$72.7 million in the first quarter 2020, representing 40% growth over the prior year quarter 

REDWOOD CITY, Calif., May 11, 2020 (GLOBE NEWSWIRE) — Codexis, Inc. (Nasdaq: CDXS), a leading protein engineering company, announces that management will present at the UBS Virtual Healthcare Conference on Monday, May 18 at 9:10 a.m. Eastern time (6:10 a.m. Pacific time).  A live webcast and replay of the presentation will be available on the Investors section of the company’s website, http://ir.codexis.com/.About Codexis, Inc.Codexis is a leading protein engineering company that applies its proprietary CodeEvolver® technology to develop proteins for a variety of applications, including as biocatalysts for the commercial manufacture of pharmaceuticals, fine chemicals and industrial enzymes, and enzymes as biotherapeutics and for use in molecular diagnostics. Codexis’ proven technology enables improvements in protein performance,...

AMRYT PHARMA PLC(“Amryt” or the “Company”)Q1 2020 RESULTS$44.6M unaudited Q1 revenues representing a 30% increase on unaudited combined revenues of $34.3M in Q1 2019110% quarter on quarter unaudited revenue growth in Q1 2020 versus Q4 2019 ($40.5M)$4.6M EBITDA2 delivered in Q1. Including non-cash items and share based compensation expenses, this results in an operating loss before finance expense for Q1 of $17.0MCash generated from Operating Activities of $6.2M during Q1 2020Aegerion integration successfully completed ahead of schedule, delivering positive EBITDA a quarter ahead of planRobust financial position with $67.0M in cash compared to $65.2M at December 31, 2019Enrolment in EASE global Phase 3 study concluded with top-line data expected in late Q3 / early Q4 2020FILSUVEZ® confirmed as the global brand name for AP101Confidentially...

HOUSTON, May 11, 2020 (GLOBE NEWSWIRE) — Carriage Services, Inc. (NYSE: CSV) today announced plans to release 2020 first quarter results on Tuesday, May 19, 2020 after the market closes. In conjunction with the release, Carriage Services has scheduled a conference call, which will be broadcast live over the Internet on Wednesday, May 20, 2020 at 9:30 a.m. central time.What: Carriage Services First Quarter 2020 Earnings Conference CallWhen: Wednesday, May 20, 2020 – 9:30 a.m. central timeHow: Live via phone – By dialing 866-516-3867 (conference ID 2275039) or live over the Internet by logging on to the Company’s website at www.carriageservices.com.An audio archive of the call will be available either by phone until May 25, 2020, by dialing toll-free 855-859-2056 (conference ID 2275039) or on the Company’s website at www.carriageservices.com.Carriage...

AMRYT PHARMA PLC(“Amryt” or the “Company”)FY 2019 RESULTSTransformational year of performance and growth for AmrytAegerion integration completed successfully and ahead of scheduleBusiness performing ahead of expectationsStrong year end cash balances of $65.2MUnaudited combined revenues of $154.1M in 2019, an increase of 13.1% on 2018 unaudited combined revenues of $136.3M1The Company has also today separately issued Q1 results for 2020Amryt, a global, commercial-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from serious and life-threatening rare diseases, today announces audited results for the year ended December 31, 2019. These audited results include the full year results for Amryt which include contributions from the legacy Aegerion Pharmaceuticals, Inc....

Net loss of $200.1 million for the first quarter of 2020, compared with net loss of $15.3 million for the first quarter of 2019; adjusted net loss of $11.0 million, compared with adjusted net income of $19.0 million in the first quarter of 2019 U.S. company-owned same store sales, which includes e-commerce sales, decreased 10.1% compared with the first quarter of 2019; excluding the impact of the COVID-19 pandemic, U.S. company-owned store sales decreased 4.4% Approximately 1,100, or 30%, of the U.S. and Canada company-owned and franchise retail stores were closed due to the COVID-19 pandemic as of March 31, 2020  PITTSBURGH, May 11, 2020 (GLOBE NEWSWIRE) — GNC Holdings, Inc. (NYSE: GNC) (the “Company”) reported consolidated revenue of $472.6 million in the first quarter of 2020, compared with consolidated revenue of $564.8 million...

Name of issuer: NATIXIS – joint stock company (“SA”) with a share capital of €5,049,354,392.00Registered under nr. B 542 044 524 RCS ParisRegistered office: 30 avenue Pierre Mendès-France, 75013 Paris* Net total: total number of voting rights attached to the total number of shares – shares without voting rights (treasury stock, etc.)The €5,049,354,392.00 share capital has been registered by a decision of the Chief Executive Officer on March 1er, 2020.Note: This translation is for information purposes only. In case of inconsistencies between the French version and the English version of this document, the French version shall prevailAttachmentNumber of shares and voting rights_APRIL_30_2020